# A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

> **NCT05225558** · PHASE2 · TERMINATED · sponsor: **LigaChem Biosciences, Inc.** · enrollment: 40 (actual)

## Conditions studied

- MRSA Bacteremia

## Interventions

- **DRUG:** Delpazolid
- **DRUG:** Vancomycin
- **DRUG:** Placebo of Delpazolid

## Key facts

- **NCT ID:** NCT05225558
- **Lead sponsor:** LigaChem Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-26
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-03-18
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Early termination; Difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225558, "A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05225558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*